CBD for Health and Wellness:

CBD Gets High Ratings, But Questions Remain

As part of our research on CBD for Health and Wellness: U.S. Market Analysis and Opportunities, Kline & Company has completed a second large-scale consumer attitudes and usage study on CBD. Adult U.S. consumers aged 21 and over make up the sample of nearly 700 consumers nationwide. Awareness is widespread and many consumers have tried CBD, but there are still numerous unanswered questions when it comes to usage.Continue reading

Natural Personal Care

The Future of Naturals at Vivaness 2020

Naturals are here to stay and have penetrated all categories, showing dynamic growth even in the previously underserved ones, including oral care, deodorants, and feminine care products. The revelations were made last week when Kline’s Naira Aslanian took to the floor with a fascinating presentation, “The Future of the Natural Beauty Market,” at the Vivaness International Trade Fair for Naturals and Organic Personal Care products in Nuremberg, Germany.

Continue reading

Cannabis in Food & Beverages

U.S. Marketers Bet Big on Cannabis-Infused Products

Cannabis has emerged as the new buzzword across many U.S. industries as a result of the 2018 Farm Bill, which legalized the cultivation, sale, and distribution of hemp. The overall market for cannabis-infused food and beverages achieved strong double-digit growth of over 70% in 2019, while CBD health and wellness products are expected to approach $1 billion by 2024 with strong growth each year. Driving market growth is strong word-of-mouth and growing consumer interest in new and natural ingredients.Continue reading

Cannabis Coffee

Cannabis in Food & Beverages: The Dawn of a New Era

Cannabis has been popping up as the “it” ingredient everywhere, from skin creams to pain relievers and now food and beverages. The food & beverage industry in the United States is on the verge of crossing a new threshold due to changing consumer perceptions and the growing acceptance of CBD, combined with substantial investments being made in this market by private equity firms, start-ups, and leading beverage companies alike.

As a plant, cannabis benefits from the halo effect of being natural and “good for you,” which plays well into overarching consumer demand for natural and health-conscious products. CBD has already started to impact other consumer packaged goods industries, including the beauty and personal care and nonprescription drug markets.Continue reading

Consumer Cannabis Blog 1

What does passage of the Farm Bill mean for health and personal care CBD marketers?

On December 12, 2018, the U.S. Congress passed the Agricultural Improvement Act of 2018, otherwise known as the Farm Bill. The bill legalizes the production and transportation of hemp and hemp products, among other things. The Farm Bill has been sent to President Trump, who is expected to sign off on it before the end of the year. Marketers of health and beauty products containing Cannabidiol (CBD), which can be sourced from hemp, have anxiously awaited passage of the Farm Bill in the hopes that it will expand the U.S. market for consumer CBD products. However, this market is still burgeoning, and uncertainty about the legality of marketing CBD products nationwide continues to perplex marketers and retailers.

The Farm Bill defines “hemp” as “the plant Cannabis sativa L. and any part of the plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol [THC] concentration of not more than 0.3 percent on a dry weight basis.” While the definition of hemp will include any part of the Cannabis sativa L. plant, it retains prior regulatory limits used to define industrial hemp by limiting permissible levels of THC concentrations to no more than 0.3%. Hemp and hemp products that meet this definition will be exempt from the definition of “marihuana” (or marijuana) under the Federal Controlled Substances Act, thereby removing it from the list of prohibited Schedule I drugs.

Continue reading